Combination therapy for treating cancer
The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.
1. A method for treating a malignant rhabdoid tumor (MRT) or an atypical teratoid/rhabdoid tumor (AT/RT) comprising administering to a subject:
(tazemetostat), or a pharmaceutically acceptable salt thereof, and
(b) panobinostat.
2. The method of claim 1 , wherein panobinostat is administered prior to the tazemetostat or the pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein tazemetostat, or the pharmaceutically acceptable salt thereof, is administered prior to panobinostat.
4. A method for treating a malignant rhabdoid tumor (MRT) or an atypical teratoid/rhabdoid tumor (AT/RT), comprising sensitizing a subject, wherein the sensitizing comprises administering to the subject:
(a)
(tazemetostat), or a pharmaceutically acceptable salt thereof, and
(b) panobinostat.
5. The method of claim 1 , wherein the method is for treating a malignant rhabdoid tumor (MRT).
6. The method of claim 1 , wherein the method is for treating an atypical teratoid/rhabdoid tumor (AT/RT).
7. The method of claim 4 , wherein the method is for treating a malignant rhabdoid tumor (MRT).
8. The method of claim 4 , wherein the method is for treating an atypical teratoid/rhabdoid tumor (AT/RT).